EX-99.1

Exhibit 99.1

Burning Rock Reports Second Quarter 2026 Financial Results

GUANGZHOU, China, September 10, 2026—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2026.

Recent Business Updates

•

Therapy Selection & MRD

•

OncoScreen^® BCMatch Tissue Kit has officially entered the Priority Review Channel of the Center for Medical Device Evaluation (CMDE) under the NMPA.

•

CanCatch Custom Kit and CanCatch Custom Kit (cPAS) have officially entered the Special Review Procedure for Innovative Medical Devices of CMDE under the NMPA.

•

In August 2026, the Priority Review Channel application for OncoCompass Target Cancer Mutation Profiling Liquid Kit was resubmitted and subsequently accepted for review.

“After navigating a challenging first quarter, we delivered the anticipated sequential recovery in the second quarter, offsetting the order volatility in the first quarter” said Mr. Yusheng Han, Chairman and Chief Executive Officer of Burning Rock. “With several products having entered the Priority Review Channel and Special Review Procedure for Innovative Medical Devices of CMDE and new registration certificates expected in the coming quarters, we are confident that we will achieve sustainable and meaningful top-line growth over the long term.”

Second Quarter 2026 Financial Results

Revenues were RMB134.7 million (US$19.9 million) for the three months ended June 30, 2026, representing a 9.3% decrease from RMB148.5 million for the same period in 2025.

•

Revenue generated from central laboratory business was RMB36.8 million (US$5.4million) for the three months ended June 30, 2026, representing a 10.0% decrease from RMB40.9 million for the same period in 2025, primarily attributable to a decrease in the number of tests, as we continued our transition towards in-hospital business.

•

Revenue generated from in-hospital business was RMB67.1 million (US$9.9 million) for the three months ended June 30, 2026, representing a 7.4% increase from RMB62.5 million for the same period in 2025, driven by an increase in sales volume.

•

Revenue generated from pharma research and development services was RMB30.8 million (US$4.6 million) for the three months ended June 30, 2026, representing a 31.8% decrease from RMB45.1 million for the same period in 2025, primarily attributable to decreased testing services performed for our pharma customers.

Cost of revenues was RMB36.9 million (US$5.5 million) for the three months ended June 30, 2026, representing an 8.6% decrease from RMB40.4 million for the same period in 2025.

Gross profit was RMB97.8 million (US$14.4 million) for the three months ended June 30, 2026, representing a 9.5% decrease from RMB108.1 million for the same period in 2025. Gross margin was 72.6% for the three months ended June 30, 2026, compared to 72.8% for the same period in 2025. By channel, gross margin of central laboratory business was 85.7% for the three months ended June 30, 2026, compared to 87.9% during the same period in 2025, primarily driven by an increased depreciation; gross margin of in-hospital business was 77.1% for the three months ended June 30, 2026, compared to 74.4% during the same period in 2025, primarily attributable to an increase in sales volume to high margin products; gross margin of pharma research and development services was 47.2% for the three months ended June 30, 2026, compared to 56.8% during the same period of 2025, primarily due to a decrease in test volume of higher-margin projects.

Non-GAAP gross profit, which excludes depreciation and amortization expenses, was RMB100.1 million (US$14.8 million) for the three months ended June 30, 2026, representing a 9.4% decrease from RMB110.5 million for the same period in 2025. Non-GAAP gross margin was 74.3% for the three months ended June 30, 2026, compared to 74.4% for the same period in 2025. For more details on these non-GAAP financial measures, please see the table captioned “Reconciliations of GAAP and Non-GAAP Results” set forth at the end of this press release.

Operating expenses were RMB115.8 million (US$17.1 million) for the three months ended June 30, 2026, representing a 3.2% decrease from RMB119.6 million for the same period in 2025. The decrease was primarily driven by business cost control to improve operating efficiency.

•

Research and development expenses were RMB31.2 million (US$4.6 million) for the three months ended June 30, 2026, representing a 37.3% decrease from RMB49.8 million for the same period in 2025, primarily due to a temporary decrease across different research phases.

•

Selling and marketing expenses were RMB47.1 million (US$6.9 million) for the three months ended June 30, 2026, representing a 22.7% increase from RMB38.4 million for the same period in 2025, primarily due to an increase in staff costs.

•

General and administrative expenses were RMB37.5 million (US$5.6 million) for the three months ended June 30, 2026, representing a 19.2% increase from RMB31.4 million for the same period in 2025, primarily due to an increase in allowance for credit loss in relation to accounts receivables, partially offset by a decrease in share-based compensation expenses.

Net loss was RMB18.4 million (US$2.7 million) for the three months ended June 30, 2026, compared to RMB9.7 million for the same period in 2025.

Cash, cash equivalents and restricted cash were RMB419.1 million (US$61.8 million) as of June 30, 2026.

Exchange Rate Information

This press release contains translations of certain Renminbi amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars and from U.S. dollars to Renminbi are made at a rate of RMB6.7851 to US$1.00, the exchange rate on June 30 2026, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the Renminbi or U.S. dollars amounts referred could be converted into U.S. dollars or Renminbi, as the case may be, at any particular rate or at all.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: ir.brbiotech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements.

Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Non-GAAP Measures

In evaluating the business, the Company considers and uses non-GAAP measures, such as non-GAAP gross profit and non-GAAP gross margin, as supplemental measures to review and assess operating performance and formulate business plans. However, the presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These non-GAAP financial measures may be different from non-GAAP methods of accounting and reporting used by other companies, including peer companies, and therefore their comparability may be limited.

The Company defines non-GAAP gross profit as gross profit excluding depreciation and amortization. The Company defines non-GAAP gross margin as non-GAAP gross profit divided by its revenue.

The Company believes presenting non-GAAP gross profit and non-GAAP gross margin excluding non-cash impact of depreciation and amortization, in addition to the Company’s GAAP gross profit and gross margin, provides a better understanding of the underlying trends in the Company’s operating business performance.

Reconciliation of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures are set forth at the end of this press release, all of which should be considered when evaluating the Company’s performance.

Contact: IR@brbiotech.com

Selected Operating Data


	As of
	June 30, 2025		September 30, 2025		December 31, 2025		March 31, 2026		June 30, 2026
In-hospital channel:
Pipeline partner hospitals⁽¹⁾		30		31		30		30		30
Contracted partner hospitals⁽²⁾		63		63		64		64		64
Total number of partner hospitals		93		94		94		94		94

(1)	Refers to hospitals that are in the process of establishing in-hospital laboratories, laboratory equipment procurement or installation, staff training or pilot testing using the Company’s products.

(2)	Refers to hospitals that have entered into contracts to purchase the Company’s products for use on a recurring basis in their respective in-hospital laboratories the Company helped them establish. Kit revenue is generated from contracted hospitals.

Selected Financial Data


	For the three months ended
Revenues	June 30, 2025		September 30, 2025		December 31, 2025		March 31, 2026		June 30, 2026
			(RMB in thousands)
Central laboratory channel		40,861		36,811		44,025		32,420		36,782
In-hospital channel		62,496		52,847		51,005		52,761		67,145
Pharma research and development channel		45,197		41,959		31,285		22,762		30,838
Total revenues		148,554		131,617		126,315		107,943		134,765

For the three months ended

Revenues by location of contracting customer

June 30,
2025

September 30,
2025

December 31,
2025

March 31,
2026

June 30,
2026

(RMB in thousands)

Overseas

37,458

17,214

21,849

8,544

17,878

Chinese mainland

111,096

114,403

104,466

99,399

116,887

Total revenues

148,554

131,617

126,315

107,943

134,765


	For the three months ended
Gross profit	June 30, 2025		September 30, 2025		December 31, 2025		March 31, 2026		June 30, 2026
			(RMB in thousands)
Central laboratory channel		35,937		30,126		39,322		28,761		31,510
In-hospital channel		46,490		37,925		38,388		38,458		51,760
Pharma research and development channel		25,676		30,793		20,856		10,789		14,543
Total gross profit		108,103		98,844		98,566		78,008		97,813


	For the three months ended
Share-based compensation expenses	June 30, 2025			September 30, 2025		December 31, 2025		March 31, 2026			June 30, 2026
				(RMB in thousands)
Cost of revenues		280			301		300		82			141
Research and development expenses		(270	)		73		259		(345	)		345
Selling and marketing expenses		364			624		748		164			269
General and administrative expenses		2,005			2,831		1,815		1,907			1,244
Total share-based compensation expenses		2,379			3,829		3,122		1,808			1,999

Burning Rock Biotech Limited

Unaudited Condensed Statements of Comprehensive Loss

(in thousands, except for number of shares and per share data)


	For the three months ended
	June 30, 2025			September 30, 2025			December 31, 2025			March 31, 2026			June 30, 2026			June 30, 2026
	RMB			RMB			RMB			RMB			RMB			US$
Revenues		148,554			131,617			126,315			107,943			134,765			19,862
Cost of revenues		(40,451	)		(32,773	)		(27,749	)		(29,935	)		(36,952	)		(5,446	)

Gross profit		108,103			98,844			98,566			78,008			97,813			14,416
Operating expenses:
Research and development expenses		(49,770	)		(41,469	)		(34,866	)		(27,559	)		(31,230	)		(4,603	)
Selling and marketing expenses		(38,413	)		(41,808	)		(44,066	)		(41,206	)		(47,141	)		(6,948	)
General and administrative expenses		(31,417	)		(31,698	)		(31,672	)		(28,088	)		(37,443	)		(5,518	)

Total operating expenses		(119,600	)		(114,975	)		(110,604	)		(96,853	)		(115,814	)		(17,069	)

Loss from operations		(11,497	)		(16,131	)		(12,038	)		(18,845	)		(18,001	)		(2,653	)
Interest income		2,226			1,744			1,502			1,261			1,370			202
Interest expense		—			(15	)		(15	)		(15	)		(15	)		(2	)
Other income (expense), net		387			7			1			294			(199	)		(29	)
Foreign exchange (loss) gain, net		(574	)		(2,151	)		(3,960	)		65			(1,278	)		(188	)

Loss before income tax		(9,458	)		(16,546	)		(14,510	)		(17,240	)		(18,123	)		(2,670	)
Income tax expenses		(244	)		(212	)		(876	)		(232	)		(287	)		(42	)

Net loss		(9,702	)		(16,758	)		(15,386	)		(17,472	)		(18,410	)		(2,712	)

Net loss attributable to Burning Rock Biotech Limited’s shareholders		(9,702	)		(16,758	)		(15,386	)		(17,472	)		(18,410	)		(2,712	)
Net loss attributable to ordinary shareholders		(9,702	)		(16,758	)		(15,386	)		(17,472	)		(18,410	)		(2,712	)
Loss per share for class A and class B ordinary shares:
Class A ordinary shares - basic and diluted		(0.09	)		(0.16	)		(0.15	)		(0.17	)		(0.17	)		(0.02	)
Class B ordinary shares - basic and diluted		(0.09	)		(0.16	)		(0.15	)		(0.17	)		(0.17	)		(0.02	)
Weighted average shares outstanding used in loss per share computation:
Class A ordinary shares - basic and diluted		90,357,970			90,416,619			87,444,109			87,871,026			91,279,393			91,279,393
Class B ordinary shares - basic and diluted		17,324,848			17,324,848			17,324,848			17,324,848			17,324,848			17,324,848
Other comprehensive loss, net of tax of nil:
Foreign currency translation adjustments		(243	)		(1,724	)		(2,050	)		(3,143	)		(2,971	)		(438	)
Total comprehensive loss		(9,945	)		(18,482	)		(17,436	)		(20,615	)		(21,381	)		(3,150	)
Total comprehensive loss attributable to Burning Rock Biotech Limited’s shareholders		(9,945	)		(18,482	)		(17,436	)		(20,615	)		(21,381	)		(3,150	)

Burning Rock Biotech Limited

Unaudited Condensed Consolidated Balance Sheets

(In thousands)


	As of
	December 31, 2025		June 30, 2026		June 30, 2026
	RMB		RMB		US$
ASSETS
Current assets:
Cash and cash equivalents		478,392		416,818		61,431
Restricted cash		2,696		2,290		338
Accounts receivable, net		169,611		172,768		25,463
Contract assets, net		12,301		9,777		1,441
Inventories, net		48,576		34,131		5,030
Contract costs		8,399		5,597		825
Prepayments and other current assets		18,611		22,636		3,337

Total current assets		738,586		664,017		97,865
Non-current assets:
Property and equipment, net		31,099		31,808		4,688
Operating right-of-use assets		42,774		46,282		6,821
Intangible assets, net		284		233		35
Other non-current assets		7,632		8,271		1,219

Total non-current assets		81,789		86,594		12,763
TOTAL ASSETS		820,375		750,611		110,628

Burning Rock Biotech Limited

Unaudited Condensed Consolidated Balance Sheets (Continued)

(in thousands)


	As of
	December 31, 2025			June 30, 2026			June 30, 2026
	RMB			RMB			US$
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable		40,744			17,950			2,646
Deferred revenue		107,819			109,170			16,090
Accrued liabilities and other current liabilities		80,861			68,458			10,090
Customer deposits		592			592			87
Current portion of long-term borrowings		200			200			29
Current portion of operating lease liabilities		16,762			21,172			3,120
Total current liabilities		246,978			217,542			32,062

Non-current liabilities:
Long-term borrowings		1,700			1,600			236
Non-current portion of operating lease liabilities		24,458			22,140			3,263
Other non-current liabilities		11,975			12,248			1,805

Total non-current liabilities		38,133			35,988			5,304
TOTAL LIABILITIES		285,111			253,530			37,366

Shareholders’ equity:
Class A ordinary shares		120			126			19
Class B ordinary shares		21			21			3
Additional paid-in capital		5,010,060			5,013,867			738,953
Treasury stock		(57,193	)		(57,193	)		(8,429	)
Accumulated deficits		(4,255,607	)		(4,291,489	)		(632,487	)
Accumulated other comprehensive loss		(162,137	)		(168,251	)		(24,797	)
Total shareholders’ equity		535,264			497,081			73,262

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		820,375			750,611			110,628

Burning Rock Biotech Limited

Unaudited Condensed Statements of Cash Flows

(in thousands)


	For the six months ended
	June 30, 2025			June 30, 2026			June 30, 2026
	RMB			RMB			US$
Net cash used in operating activities		(67,876	)		(51,657	)		(7,613	)
Net cash used in investing activities		(1,324	)		(2,841	)		(419	)
Net cash generated from/(used in) financing activities		2,000			(100	)		(15	)
Effect of exchange rate on cash, cash equivalents and restricted cash		62			(7,382	)		(1,088	)
Net decrease in cash, cash equivalents and restricted cash		(67,138	)		(61,980	)		(9,135	)
Cash, cash equivalents and restricted cash at the beginning of period		522,162			481,088			70,904
Cash, cash equivalents and restricted cash at the end of period		455,024			419,108			61,769

Burning Rock Biotech Limited

Reconciliations of GAAP and Non-GAAP Results


	For the three months ended
	June 30, 2025			September 30, 2025			December 31, 2025			March 31, 2026			June 30, 2026
				(RMB in thousands)
Gross profit:
Central laboratory channel		35,937			30,126			39,322			28,761			31,510
In-hospital channel		46,490			37,925			38,388			38,458			51,760
Pharma research and development channel		25,676			30,793			20,856			10,789			14,543
Total gross profit		108,103			98,844			98,566			78,008			97,813
Add: depreciation and amortization:
Central laboratory channel		456			231			490			412			548
In-hospital channel		389			372			308			228			297
Pharma research and development channel		1,528			1,491			2,057			1,885			1,425
Total depreciation and amortization included in cost of revenues		2,373			2,094			2,855			2,525			2,270
Non-GAAP gross profit:
Central laboratory channel		36,393			30,357			39,812			29,173			32,058
In-hospital channel		46,879			38,297			38,696			38,686			52,057
Pharma research and development channel		27,204			32,284			22,913			12,674			15,968
Total non-GAAP gross profit		110,476			100,938			101,421			80,533			100,083
Non-GAAP gross margin:
Central laboratory channel		89.1	%		82.5	%		90.4	%		90.0	%		87.2	%
In-hospital channel		75.0	%		72.5	%		75.9	%		73.3	%		77.5	%
Pharma research and development channel		60.2	%		76.9	%		73.2	%		55.7	%		51.8	%
Total non-GAAP gross margin		74.4	%		76.7	%		80.3	%		74.6	%		74.3	%